Endeavour Silver Corp vs Immunovant Inc. Common Stock — how do they compare? Endeavour Silver Corp trades at $8.75 (market cap $2.46B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Immunovant Inc. Common Stock is far larger — about 2.7× Endeavour Silver Corp's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Immunovant Inc. Common Stock for 0 Days on average.
| EXK | IMVT | |
|---|---|---|
Market Cap | $2.46B | $6.62B |
Volume | 5,827,665 | 1,131,364 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $44.96 |
52-Week Low | $7.07 | $17.03 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $2.47B | $5.72B |
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.32, down 4.04% on the day, amid a bearish technical signal. The company reported a net loss of $119.1M in 2025 but expects a significant turnaround in 2026 with projected net income of $66M. Recent news highlights operational progress at the Terronera and Kolpa mines, though temporary disruptions have occurred. Analyst consensus is strongly bullish with a $10.50 price target, but technical indicators show selling pressure.
The outlook is mixed: strong analyst support and projected profitability in 2026 present upside, but near-term technical weakness and operational risks like mine blockades pose challenges. The stock's valuation multiples are elevated relative to current earnings, requiring successful execution of growth plans to justify further gains.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →